Lifeway Foods® Delivers Highest Quarterly Net Sales in Company History, Extending Record Growth in Second Quarter 2026

Lifeway Foods, Inc. (LWAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeway Foods® Delivers Highest Quarterly Net Sales in Company History, Extending Record Growth in Second Quarter 2026 $66.9 million in net sales, up 24.1% year-over-year and $3.9 million above the prior quarterly record 27th consecutive quarter of year-over-year net

Original reporting
Published Aug 13, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LWAY
Bullish
medium confidence
Mentioned
$LWAY
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LWAYBullishMed
01

Why it matters

Traders can update models for revenue growth durability, margin sensitivity to milk and packaging/transport costs, and the expected timing of gross margin and profitability recovery in 2027.

02

Market read

Record quarterly net sales growth contrasts with sharp gross margin compression, while management expects normalization and full margin recovery in 2027 alongside distribution gains and Waukesha expansion.

03

What to watch

SG&A as a percent of sales rose to 18.4% in Q2, so operating leverage may be slower than revenue growth implies; also, the Waukesha expansion is planned for early 2027, so execution risk could affect the recovery path.

Relevance 7/10Novelty 8/10Timing: filed pre-market today, Q2 results and 2027 margin recovery outlook

Background

SEC Form 8-K Item 2.02 with Exhibit 99.1 press release covering Lifeway Foods Q2 2026 results and financial condition.

Company-level read

Ticker impact

$LWAYBullishMedium confidence
Context

Lifeway reports Q2 2026 net sales of $66.9M (+24.1% YoY) but gross margin falls to 19.5% from 28.6% due to elevated milk prices.

Expected impact

Likely positive bias on revenue momentum, with potential volatility as traders weigh margin compression and the credibility/timing of 2027 gross margin recovery.

Evidence & confidence

This is a primary earnings-style disclosure with specific quarterly and YTD figures plus explicit forward-looking statements about margin recovery in 2027 and a Waukesha expansion timeline in early 2027.

Market effects

Highlights cost-driven margin pressure in cultured dairy/probiotic foods and the importance of pricing power and packaging/transport cost pass-through.

Limited direct regional read-through beyond US dairy input cost dynamics.

Low; primarily US-focused distribution and conventional milk cost outlook references.

Counterpoint

Margin recovery in 2027 is guidance, not a realized datapoint; if milk prices or resin/transport costs stay elevated longer, earnings leverage could disappoint despite strong top-line growth.

Key entities

  • Lifeway Foods, Inc.

    Nasdaq-listed kefir and fermented probiotic foods supplier reporting Q2 2026 results and 2027 margin recovery expectations.

  • Julie Smolyansky

    President and CEO quoted on record net sales, temporary margin headwind, and 2027 recovery outlook.

Related articles

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Q3 Earnings Call Highlights

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

$GOHighAI 8/10

What Grocery Outlet (GO) Said on Its Q3 Earnings Call

Grocery Outlet (GO) reported Q3 adjusted earnings of $0.16 per share, down from $0.21 a year earlier, with adjusted EBITDA falling to $59.4 million. The company cited promotional spending, higher supply chain costs, and increased produce shrink for the decline. GO forecasted Q4 comparable-store sales growth of 1.5% to 2.5% and adjusted earnings of $0.11 to $0.14 per share. The company plans to open 20-31 net new stores in 2027, all in existing markets.

$CAPRLow

Capricor Therapeutics Q3 Earnings Call Highlights

Capricor Therapeutics reported a Q3 net loss of $42.7M, widening from $24.6M a year earlier. The company highlighted positive data on Deramiocel, its lead therapy, showing improved upper limb function in patients. Capricor is preparing for a potential launch while resolving a distribution dispute with Nippon Shinyaku. The company has sufficient cash to fund operations for at least 12 months.

$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

$ATROMed

Astronics Q3 Earnings Call Highlights

Astronics reported Q3 net income of $52.2M ($1.08 per share), up from a loss a year earlier. Revenue grew 40% in Test Systems to $26.2M, driven by Army programs. Backlog was $780M. The company expects 2026 revenue of $1.02B-$1.04B and growth over 10% in 2027. Debt fell to $284.8M, and cash flow was $25.8M.